Agonist News and Research

RSS

Delay in seeking emergency medical care for asthma exacerbations can result in worse outcomes

Waiting to seek emergency medical care for asthma exacerbations can result in worse outcomes, including hospitalization, according to a study conducted by researchers from New York.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

Insights into psychiatric disorders

Social deficits are common in several psychiatric disorders, including autism spectrum disorders and schizophrenia. Individuals with severe social dysfunction can experience significant difficulties with everyday functioning.

5 May 2011

Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting

Pearl Therapeutics Inc. announced today that complete results from the Company's Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society.

30 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Diabetes and prediabetes are on the rise: New medication in research trials

As the newest statistics from the CDC show, diabetes is an ever increasing problem for Americans. Almost 26 million adults in this country now have diabetes, an increase of 9% since 2008. Ninety to 95% of cases are type 2 diabetes, marked by a gradual inability of the body’s cells to respond to insulin, and eventually an inability to produce enough insulin. In addition, almost 79 million people in this country have prediabetes. The CDC has warned that if diabetes continues on its current course, it could affect a third of all adult Americans by 2050.

26 Apr 2011

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011